SWISS EXCHANGE · NVS

+2.41% · +$3.76 · Vol 1.2M

After hours · updated 19:09:25 ET

Novartis AG

Pharmaceuticals

$160.00

Card

Relationship Map

Veridion Score

Refresh

Score snapshot refresh in progress

Veridion Score History · 90D

Score not reportedVeridion does not publish a score-history trend for NVS until the ticker has a real scored snapshot. No trend is implied for this page.Review methodology

AI Analysis

Sovereign

Why is NVS moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

Catalyst calendar

What can move NVS next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Congress

Upcoming

No dated upcoming catalyst is present in the current source window.

Recent

Mar 31
CongressChecking access
Alan Armstrong purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Mar 30
CongressChecking access
Alan Armstrong purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Mar 13
CongressChecking access
Ro Khanna sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Feb 13
CongressChecking access
Ro Khanna sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Oct 31
CongressChecking access
Lisa C. McClain sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Sep 25
CongressChecking access
Lisa Mcclain sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Sep 11
CongressChecking access
Lisa Mcclain purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jul 22
CongressChecking access
Lisa Mcclain sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access

About Novartis AG

Pharmaceuticals

Listed since

1996

Employees

75K

Country

Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$156.17

Day high

$159.72

Day low

$156.10

Previous close

$156.24

52W high

$168.62

-5.11% from high

52W low

$121.80

82% of range

Market cap

$297B

P/E

21.95×

EPS

$6.62

Beta

0.05

Shares out

1.9B

Volume

1.2M

0.71× rel vol

Avg volume

1.7M

VWAP

$158.73

Price history computed in-house

+6.04%

+4.52%

+5.26%

+26.16%

YTD

+16.05%

SMA 50 $154.33 · above

SMA 200 $148.25 · above

52W position 82%

NVS overview

Veridion Score

Not reported

Latest receipt rows

Alan Armstrong · Purchase

13F holders

None on file

Relationship mapTrace receipt-backed holders and filings around NVS.Congress disclosuresOpen receipt and filing context for NVS.MethodologyReview score inputs, coverage rules, and limitations.

SEC Form 4 ledger

NVS insider activity

Novartis AG

Score

Not evaluated

Pressure

Not evaluated

Filings

Buys / sells

0 / 0

Net value

Not evaluated

Insiders

Cluster

Not evaluated: the SEC filing index could not be read

Net pressure

Not evaluated: no value-bearing Form 4 rows are loaded.

Convergence not evaluated

No value-bearing Form 4 rows are loaded, so cross-source convergence is not evaluated.

No value-bearing Form 4 rows

The current Form 4 feed did not return value-bearing open-market rows for NVS.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology

Public disclosures

Congress activity in NVS

Congress tracker Open ticker disclosure ledger →

Alan ArmstrongBuyself

Novartis AG Common Stock · Transaction Mar 31, 2026 · Filed Jul 21, 2026 · $1,001 to $15,000

Official filing ↗

Alan ArmstrongBuyself

Novartis AG Common Stock · Transaction Mar 30, 2026 · Filed Jul 21, 2026 · $15,001 to $50,000

Official filing ↗

Ro KhannaSell

NVS Common Stock · Transaction Mar 13, 2026 · Filed Apr 7, 2026 · Amount pending receipt enrichment

Official filing ↗

Ro KhannaSell

NVS Common Stock · Transaction Feb 13, 2026 · Filed Mar 9, 2026 · Amount pending receipt enrichment

Official filing ↗

Lisa C. McClainSellspouse

Novartis AG Common Stock · Transaction Oct 31, 2025 · Filed Nov 21, 2025 · $1,001 to $15,000

Official filing ↗

Federal contracts

NVS contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed

Refresh interval: 12hSource: Federal contract awards

No federal contracts on file for NVS in this window.

Lobbying spend

NVS lobbying filings, year to date.

Registered lobbying filings matched to Novartis AG.

Not disclosed

Refresh interval: 12hSource: LDA disclosure filings

No lobbying filings on file for NVS in this window.

Analyst ratings

Sovereign unlock shows live analyst consensus for NVS.

Options

Sovereign unlock shows live options positioning for NVS.

Related tickers

Cross-references from this score page.

Apprentice · 1 rail

Similar headline score

Nearest public composite scores. Factor similarity requires Sovereign.

Methodology

No related ticker met the data requirements for this rail.

Why is NVS moving today?

What can move NVS next.

NVS overview

Related filings and maps

NVS insider activity

NVS contract awards, year to date.

NVS lobbying filings, year to date.

Cross-references from this score page.

What can move NVS next.

NVS insider activity

Cross-references from this score page.